Times are changing and so are we – VelaLabs has grown up and is now moving into the next evolving step of the organization. The former Co-founder and COO of VelaLabs could be onboarded as new Managing Director of VelaLabs GmbH replacing the very successful management board Markus Roucka, Albert Lauss and Klaus Hajszan. Within the last 4 years, the management board almost tripled the turnover and the number of employees started 2019 with 43 and is now close to 100 employees.
Bringing back Dr. Andreas Nechansky will further drive the innovative way of thinking, and will expand the client base for state-of-the-art analytical services.
But who is the new managing director?
Dr Andreas Nechansky received his PhD in the field of Molecular Biology from the University of Vienna. He started his academic career with two PostDoc positions at Novartis Vienna (1998-2000) and the Scripps Research Institute in La Jolla, US (2001-2002), working in the field of antibody generation/characterization. In 2003, he joined the Austrian Biotech company Igeneon as Project Leader for three pre-clinical assets. In 2005 he was promoted to Head Analytical Development. In 2006 he Co-founded VelaLabs and from then on served as COO and for 3 years as Head of Quality control. In 2015 he joined the Biosimilar company Eden as VP Analytical Operations and moved to Taiwan. He was responsible for setting up all analytical assays required for biologics comparability studies. In 2019 he re-located back to Austria where he became Site Manager and subsequently Managing Director of ABF Pharmaceutical Services. He is a certified EU Qualified Person and has published 20+ analytical papers in peer reviewed journals.
With this background and knowledge of analytical services, he is a perfect fit checking a lot of boxes. He can rely on a very competent team and broad collaboration within VelaLabs.
What's next on the plate for the previous management board?
“It was a great chance and big opportunity back in 2019 and a joyful journey. There were many lessons learnt over the last years managing a fast-growing company resulting in a sustainable business”, says Markus Roucka. By making VelaLabs more visible and available to a new client base within Europe with strong focus on the DACH (Germany Austria Switzerland) region. The network has grown which led to strategic partnerships with Biotech & Pharma Companies in Austria and Germany. Using this momentum, Markus will take care as Head Business Development for the Tentamus DACH Holding.
Leading and hosting audits from clients all over the world, and regulatory authorities like the AGES, and US FDA and managing the quality processes of a GLP and GMP certified company can be quite challenging sometimes. But Klaus Hajszan showed his knowledge & excellence by improving the quality of a growing company. Digitalization and automation are challenges in the present and future, but powerful tools for continuous improvement. Therefore, Klaus will support the Tentamus Pharma & Med DACH companies with his valuable experience.
Albert had a long track record within the Pharma Industry (Immuno to Shire). He took care of operational topics within VelaLabs. With his knowledge and experience as contractor and service provider, he will identify processes for further improvements. Therefore, from now on he will take care of organizational optimization within Tentamus DACH Pharma & Med organizations.